Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain)

Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain) Uses, Dosage, Side Effects, Food Interaction and all others data.

Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain) is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain) in Participants With Moderately to Severely Active Crohn's Disease).

Trade Name	Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain)
Generic	Brazikumab
Brazikumab Other Names	Brazikumab, Immunoglobulin g2, anti-(human interleukin 23) (human monoclonal medi2070 heavy chain), disulfide with human monoclonal medi2070 .lambda.-chain, dimer
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Innovators Monograph

You find simplified version here Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain)